Drug Profile
Recombinant human uteroglobin - Samaritan Pharmaceuticals
Alternative Names: rUGLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Metastatin Pharmaceuticals
- Class Anti-inflammatories; Recombinant proteins; Respiratory stimulants
- Mechanism of Action Collagen receptor antagonists; Fibronectin receptor antagonists; Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (SC)
- 01 Mar 2007 Metastatin Pharmaceuticals has been acquired by Samaritan Pharmaceuticals